NCT04875195

A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab every six weeks (Q6W).

Conditions

• Hodgkin's Lymphoma
• Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Interventions

Type	Name	Description
BIOLOGICAL	Pembrolizumab	Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.

Timeline

• Start date: 2021-06-07
• Primary completion: 2023-12-14
• Completion: 2025-10-13
• First posted: 2021-05-06
• Last updated: 2025-10-29
• Results posted: 2025-02-10

Locations

27 sites across 11 countries: United States, Brazil, Canada, Czechia, France, Italy, Poland, Russia, South Africa, Turkey (Türkiye), Ukraine

Regulatory

• FDA-regulated drug study